Senior Director of Pharmaceutics, Catalent
Transitioning Peptides from Discovery to the Clinic
When does a molecule become a drug? Often considerations during peptide discovery can come into conflict with the needs of a drug development program. Identifying these potential conflicts early in the development process can reduce patient risk, project cost, and time to the clinic. The impact of early decisions such as sequence and salt selection, modifications, and choice of early characterization tools on the clinical development program will be explored to ensure faster and more efficient drug development.
Lisa Caralli is Senior Director of Pharmaceutics at Catalent San Diego. She has over 25 years of industry experience in pharmaceutical research and development. Lisa's area of expertise is analytical methods and formulation development of small molecules and peptides. Currently, she has a role in Catalent’s Science and Technology team where she works with pharmaceutical companies to identify the right development pathway for their early development drug candidates. Prior to joining the San Diego site over 12 years ago, Lisa was an Analytical Project Manager at Isis Pharmaceuticals where she worked on the chemistry, manufacturing and controls of antisense (oligonucleotide) drugs. Lisa joined Isis from Amylin Pharmaceuticals where she directed their amino acid analysis core facility and performed methods development for peptide-drug candidates. She began her career at the Immune Response Corporation studying biological markers of autoimmune diseases. Lisa holds a B.S. in Biochemistry from the University of California at Davis.